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a  b  s  t  r  a  c  t
The  health  effects  of soy  supplementation  in  (post)menopausal  women  are  still  a contro-
versial  issue.  The  aim  of  the  present  study  was  to establish  the  effect  of  the soy  isoﬂavones
(SIF)  present  in  a commercially  available  supplement  on  ovariectomized  rats and  to  inves-
tigate  whether  these  rats  would  provide  an adequate  model  to  predict  effects  of SIF  in
(post)menopausal  women.  Two  dose  levels  (i.e.  2 and  20 mg/kg  b.w.)  were  used  to  charac-
terize  plasma  bioavailability,  urinary  and  fecal  concentrations  of  SIF and  changes  in  gene
expression  in peripheral  blood  mononuclear  cells  (PBMC).  Animals  were  dosed  at 0 and  48 h
and  sacriﬁced  4 h  after  the last  dose.  A  clear  dose  dependent  increase  of SIF concentrations
in  plasma,  urine  and  feces  was  observed,  together  with  a strong  correlation  in  changes  in
gene expression  between  the  two  dose  groups.  All  estrogen  responsive  genes  and  related
biological  pathways  (BPs)  that were  affected  by the SIF  treatment  were  regulated  in  both
dose groups  in  the  same  direction  and  indicate  beneﬁcial  effects.  However,  in  general  no
correlation was  found  between  the  changes  in  gene  expression  in  rat PBMC  with  those  in
PBMC of  (post)menopausal  women  exposed  to  a comparable  dose  of the  same  supplement.
The  outcome  of  this  short-term  study  in rats  indicates  that  the  rat  might  not  be  a suitable
model  to  predict  effects  of  SIF in humans.  Although  the relative  exposure  period  in  this  rat
study is comparable  with  that  of  the  human  study,  longer  repetitive  administration  of  rats
to  SIF  may  be required  to  draw a ﬁnal  conclusion  on  the  suitability  of  the  rat  a  model  to
predict effects  of  SIF in  humans.
©  2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  underthe  CC  BY-NC-N
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. Introduction
Dietary isoﬂavones are phenolic plant compounds
ostly found in soy [1–3]. They are biologically active
nd, depending on the concentration, they have estrogen
gonist and antagonist effects due to structural similar-
ty with estradiol [4]. Therefore, they are also known as
hytoestrogens [4,5]. Soy isoﬂavones (SIF) have gained
ncreasing interest in recent years because of their poten-
ial health beneﬁts such as improvement of cardiovascular
unctions, bone mineral density, alleviation of menopausal
ymptoms and reduction of the occurrence of certain can-
ers like breast and prostate cancers [6–8]. The use of soy
roducts in the USA increased signiﬁcantly following their
pproval by U.S. Food and Drug Administration [9] and the
ecision [10] to allow food manufacturers to make cardio-
ascular health claims for soy protein products. Moreover
 number of SIF-rich supplements have become available
or over the counter sale in Western countries during the
ast decade [11]. In contrast, adverse health effects also
ave been reported [12–14], and recently the European
ood Safety Authority (EFSA) rejected some of the major
ealth claims of SIF, such as maintenance of bone mineral
ensity and reduction of vasomotor symptoms associated
ith menopause [15]. According to EFSA [15], the data
re not sufﬁcient to establish a cause–effect relationship
or these endpoints. Therefore, concern remains about the
otentially harmful effects from self-administered dosages
f these SIF rich products, which are freely available in
harmacies, health food stores and via online shopping on
nternet [6,11,12].
SIF are present in soy based foods and food supple-
ents, predominantly in their glucoside forms namely
enistin, daidzin and glycitin. Their corresponding primary
etabolites are genistein, daidzein and glycitein. These
etabolites are produced initially mainly by -glucosidase
resent in the duodenum and upper proximal jejunum
16,17] and further down in the intestinal tract by gut
icroﬂora [11,18]. These primary metabolites are known
s aglycones and considered to be the biologically active
orms of SIF [13,19]. However in the systemic circulation,
lucuronides (i.e. the secondary metabolites) are found to
e the predominant metabolites [20,21]. Therefore, enzy-
atic hydrolysis is commonly used to measure the total
glycone content in plasma [21–23]. Daidzin is one of
he major soy glucosides present in the soy supplements.
pproximately 20–30% of the Western population is able to
etabolize the aglycone form of daidzin (diadzein), into the
ore potent metabolite equol, which is more bioavailable
nd has a higher binding afﬁnity for the estrogen receptors
24–26]. This means that especially in (post)menopausal
quol-producing women SIF supplementation will result
n a considerable exposure related contribution to endoge-
ous estrogen levels [27–29].
The effects of SIF are thought to be induced via estrogen
eceptors (ERs) [30,31] of which an alpha and beta form
xist. SIF can regulate transcription of ER target genes via
he estrogen-responsive elements (EREs) present within
ene promoter regions in target tissues such as breast
nd uterus. It is known that activation of ER stimulates
ell proliferation, whereas ER is involved in inhibition oforts 2 (2015) 308–321 309
proliferation and stimulation of apoptosis [20,32]. Estradiol
(E2) is ER selective, whereas SIF are ER selective [15,32].
Because (post)menopausal women produce low levels of
endogenous estradiol, it is expected that the intake of SIF by
equol-producing (post)menopausal women  will result in
beneﬁcial health effects of SIF supplementation [3,6,19,33].
During the past decade, the application of microar-
ray technology has opened up new opportunities to study
the effects of food and food supplements in the control
of cellular processes. Understanding of the bioavailability,
metabolism and induction of gene expression related to dif-
ferent biological processes is key to understand the health
effects of SIF supplementation. There is, however, a lack
of information whether data obtained from in vivo stud-
ies in experimental animals are suitable to predict human
risks or beneﬁts. Hence the aim of the present study was  to
establish the effect of SIF on plasma bioavailability and gene
expression changes in ovariectomized rats and to investi-
gate whether these rats would be an adequate model to
predict effects of SIF supplementation in (post)menopausal
women. The ovariectomized rats, mimicking the hormonal
condition of (post)menopausal women, were dosed with a
commercial SIF containing supplement. The bioavailability
and the excretion of SIF were studied by measuring the con-
centration of SIF and the main metabolite equol in plasma,
urine and feces. Changes in gene expression of periph-
eral blood mononuclear cells (PBMC) were characterized,
because this could be a basis for rat to human comparison,
since PBMC are easy to collect as marker tissue in stud-
ies with human volunteers, and are often used to predict
changes in target tissue [34]. In addition, the effects on
gene expression in rat PBMC were compared with the effect
on gene expression in PBMC of (post)menopausal equol-
producing women, who  received the same commercial SIF
supplement in a parallel study [23].
2. Materials and methods
2.1. Chemicals
Pure SIF standards (both glucosides and aglycones)
and equol were purchased from LC laboratories (Woburn,
MA,  USA). Dimethyl sulfoxide (DMSO) was  obtained
from Acros Organics (Geel, Belgium), and enterodiol, -
glucuronidase H-5 (Helix Pomatia contains 60,620 unit/g
solid), OptiprepTM and Tricine from Sigma–Aldrich (Stein-
heim, Germany). NaCl was from VWR  International
(Darmstadt, Germany) and acetonitrile and methanol from
Biosolve BV (Valkenswaard, The Netherlands). Oasis HLB
1cc, solid phase extraction cartridges from Waters (Milford,
MA,  USA).
2.2. Animals
Fifteen ovariectomized F344 inbred rats, 9–10 weeks of
age, were purchased from Harlan, (Horst, The Netherlands).
The ovariectomy was  performed at the age of 7–8 weeks by
the supplier. After 2 weeks of acclimatization the animals
were delivered at the animal facility, the Centre for Labora-
tory Animals (CKP), Wageningen University, Wageningen,
The Netherlands. F344 rats were chosen for two reasons.
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Table 1
Composition of isoﬂavone-free RMH-B diet.
Analysis % Amino acids g/kg
Crude protein 23.5 Lysine 10.5
Crude fat 5.0 Methionine 3.6
Crude ﬁber 4.3 Methionine + cystine 6.6
Starch 38.3 Cystine 3.0
Sugar 4.0 Threonine 7.4
Linoleic acid 1.5 Tryptofan 2.0
Ash 5.5 Isoleucine 7.5
Dry matter 89.8 Arginine 14.7
Phenylalanine 8.7
Energy (kJ/kg) 16,100 Histidine 4.6
Leucine 11.2
Minerals % Tyrosine 4.1
Ca 0.92 Valine 10.3
P 0.63
K 0.90 Vitamins IU/kg
Mg 0.12 Vit. A 20,500




Trace elements mg/kg Vit. K3 2.4
Fe 105.0 Vit. B1 thiamine 13.0
Mn 70.0 Vit. B2 riboﬂavin 10.7
Zn 55.0 Vit. B3 niacin 32.0
Cu 17.5 Vit. B5 pentothenic acid 11.9
Co 0.2 Vit. B6 pyridoxine 12.5
I  0.4 Vit. B9 pyridoxine 3.8





Firstly, according to US EPA [35], the inbred isogenic strain
F344 rats are sensitive to estrogenic compounds and thus
particularly suitable to study the effects of SIF. Secondly,
the use of an inbred strain will minimize the background
noise in micro-array analysis.
2.3. Housing and nutrition
After arrival at the animal facility, rats were housed in
groups (3 animals/cage) and fed an SIF free RMH-B standard
diet (ABDiets, Woerden, The Netherlands) (Table 1) ad libi-
tum. Standard housing, day-light hours and humidity were
maintained during the acclimatization period of 12 days.
The animals were 11–12 weeks of age during the experi-
ment, and had a bodyweight of 162–196 g. Animals were
placed individually in metabolic cages, 24 h before receiv-
ing the ﬁrst gavage dose.
2.4. Animal experiment
All aspects of the experimental protocol were reviewed
and approved by the Animal Welfare Committee of
Wageningen University (Wageningen, The Netherlands).
Animals (5 rats per dose group) received one gavage dose
for kinetic part, followed by a second gavage dose after 48 h
for microarray analysis. The animals were sacriﬁced 4 h
after the second dose and blood was collected for isolation
of PBMC. Based on the life duration of rat and human (i.e.
2 years and 70 years, respectively) the relative exposureorts 2 (2015) 308–321
time for rats (i.e. two  doses in 2 days, resulting in exposure
during about 0.27% of their lifespan) is roughly compara-
ble with that of the human volunteers in the parallel study
(i.e. 56 days, resulting in exposure during about 0.22% of
their lifespan). In addition, this study design allowed us
to collect samples for both kinetic and gene expression
studies using same animals, which is in accordance with
the principles of the three Rs (Replacement, Reduction,
and Reﬁnement). Different dose groups were 0 (solvent
control), 2 or 20 mg  SIF/kg b.w., where the SIF was admin-
istered in the form of a commercial soy supplement (see
Section 2.5). The low dose (LD) of 2 mg  SIF/kg b.w. is com-
parable with the maximum daily human consumption (i.e.
>100 mg/day; [3]) although the usual dose taken by women
using soy supplementation lies between 20 and 80 mg/day
[36]. However, to get a clear effect of SIF in this rat study, a
10 times higher dose (HD) (i.e. 20 mg  SIF/kg b.w.) was used
as well.
2.5. Preparation of test solutions
The commercial soy supplement, Phytosoya, was
obtained from Arkopharma (Carros, France). The total
content of the SIF present in the supplement and their com-
position were determined by HPLC and previously reported
[17]. The supplement had a total SIF content of 70.3 mg/g
supplement. The content of the three glucosides; genistin,
daidzin and glycitin was 7.54, 40.03 and 22.72 mg/g supple-
ment, respectively. The SIF content in this supplement was
in accordance with the content indicated by the supplier on
the label. On the basis of an average bodyweight of rats of
200 g, an oral gavage dose of 2 mg/kg b.w. corresponds with
0.4 mg  SIF per rat. Therefore a dose of 5.69 mg  supplement
per rat was  applied. Similarly, a 10 times higher amount
was  used for the 20 mg/kg dose group. For the administra-
tion of a bodyweight dependent gavage dose (i.e. maximum
of 1 ml  gavage/200 g b.w.), a 10 ml  stock solution (i.e. 0.5 ml
DMSO and 9.5 ml  nanopure water) containing 56.9 mg sup-
plement was prepared for the low dose group. Similarly, a
stock solution with a 10 times higher concentration was
prepared for the high dose groups. The stock solutions
were freshly prepared and were kept at room temperature
overnight. They were shaken thoroughly before use and
placed on a multi-axle-rotating-mixturemachine (CAT RM-
40, Slaufen, Germany) during the period of gavage dosing.
The control rats received a gavage dose of nanopure water
containing 5% DMSO.
2.6. Sample collection
Blood samples (∼250 l) were taken from the tail vein at
0, 10, 30 min  and 1, 2, 8, 24, 48 h after dosing and collected
in Microvette CB-300 tubes (Sarstedt AG & Co, Nümbrecht,
Germany) containing lithium heparin. Directly after col-
lecting the blood samples, plasma samples were prepared
by centrifuging the blood samples for 5 min  at 10,000 rpm
(Biofuge centrifuge, HeraeusSepatech, UK). Plasma sam-
ples were collected in Safe-lock 0.5 ml  Eppendorf tubes
(Eppendorf AG, Hamburg, Germany) which were placed on
ice to preserve degradation of the collected samples dur-
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n 50 ml  graduated sterile polypropylene tubes and ﬁnally
tored in 14 ml  round bottom tubes; the tubes were pur-
hased from Greiner bio-one (Frickenhausen, Germany).
eces samples (24 h) were collected in 30 ml  polystyrene
ubes from Greiner bio-one (Gloucestershire, UK). All the
rine and feces samples were stored at −80 ◦C until fur-
her analysis. After collection of the last blood sample
48 h after dosing), a second dose was administered to
he animals to study the effects on gene expression.
hen 4 h later the animals were sacriﬁced after anesthe-
ia with a mixture of isoﬂurane and oxygen followed by
emoval of blood from the dorsal aorta. The collected blood
as immediately transferred into 10 ml  tubes and kept
n a multi-axle-rotating-mixture machine (CAT RM-40,
taufen, Germany) to avoid clotting. This blood was used
or the isolation of PBMC. For the isolation procedure see
elow.
.7. Extraction of SIF from plasma, urine and feces
Extraction of SIF from plasma was performed with
 cc Waters Oasis HLB cartridges (Milford, MA,  USA). The
lasma extraction method included enzymatic hydrolysis
nd was performed according to Saracino and Raggi [37]
nd modiﬁed because of the small volume of the plasma
amples. In short, 50 L of plasma sample was mixed with
7 g (17 l of a stock solution of 1 mg/ml) of enterodiol
internal standard) and 275 g (22 l of a stock solution
f 12.5 mg/ml) of H. Pomatia mixture. The ﬁnal volume
as made 170 l by adding sodium-acetate (pH 5, 0.5 M).
he samples were then incubated for 18 h at 37 ◦C. After
ncubation, 830 l sodium-acetate was added, followed by
entrifugation for 10 min  at 10,000 × g, at 4 ◦C. The col-
ected supernatants were used for solid phase extraction
ollowed by evaporation of the extraction medium. Finally,
he dried extracts were re-dissolved in 75 l eluent B (i.e.
5 mM sodium phosphate, pH 2.4) and injected in the HPLC
ystem.
Extraction of SIF from urine samples was carried
ut following enzymatic hydrolysis. In short, 70 L of
rine sample was mixed with 375 g (30 l from stock
2.5 mg/ml) of H. Pomatia mixture. The samples were then
ncubated for 2 h at 37 ◦C. After incubation, 200 l pure ace-
onitrile and 100 l of 20% H3PO4 were added. The mixture
as vortexed and centrifuged for 10 min  at 10,000 × g at
◦C, and the supernatants (100 l) were collected in HPLC
ials.
Before extraction, feces samples were lyophilized and
owdered using pestle and mortar. Duplicate samples
f 0.1 g were taken from each feces sample and mixed
ith 500 l absolute ethanol followed by homogeniza-
ion using Precellys 24 (Bertin) at 6500 rpm for 30 s with
 short interval after 15 s. Samples were centrifuged for
0 min  at 13,500 × g at 4 ◦C. Finally, 200 l of the super-
atants were collected in HPLC vials for analysis. No
nzymatic hydrolysis was applied because from other
eports it is known that feces only contains aglycons, as
he gut microbiota are able to completely deconjugate all
onjugated SIF, i.e. glucosides, glucuronides or sulphates
18,38].orts 2 (2015) 308–321 311
2.8. HPLC analysis
The SIF content of the supplements was determined
according to the method of Pen˜alvo et al. [39] by HPLC
analysis with electrochemical detection. HPLC analyses
were carried out on LachromHitachi equipment (Varian,
Sugarland, TX, USA) with a L2100 masterpump, a L2100
auto-sampler and a CoulArray electrochemical detector
equipped with a high sensitivity analytical cell (model
6210, 4-sensor cell, ESA Inc., Chelmsford, MA,  USA). A data
collection system Varian Star 6.2 software was used for
controlling the instrument and collecting the data from the
electrochemical detector. A Symmetry Shield C18 column
(150 mm  × 4.6 mm,  5 m)  from Waters with a Brownlee
New guard precolumn (7 m)  (Shelton, USA) was used for
the analysis of the samples. The SIF were measured on
4 channels; 300, 500, 550, and 600 mV  and quantiﬁed at
500 mV.  The limit of detection for all SIF was 0.01 g/ml,
whereas the limit of quantiﬁcation was  0.02 g/ml. Solu-
tions of 10%, 55% and 30% acetonitrile in 25 mM sodium
phosphate (pH 2.4) were used as eluent A, B and C, respec-
tively. The injection volume for HPLC analysis was  10 l
and the ﬂow rate was 1 ml/min. The total running time
was 27 min. Elution was started with 30% of solvent B fol-
lowed by a change of solvent B as 30, 100, 100, 30 and 30%
in 0.0–0.1, 0.1–17, 17–19, 19–20 and 20–27 min, respec-
tively. The retention times for genistein, daidzein, glycitein,
equol and enterodiol were 17.5 ± 0.2, 12.8 ± 0.1, 12.1 ± 0.1,
16.3 ± 01 and 10.2 ± 0.2 min, respectively. The differences
in SIF concentrations between the dose groups and the
control were analyzed by student t-tests using Microsoft
Excel.
2.9. Isolation of PBMC, mRNA and running microarray
analysis
PBMC were isolated immediately after blood collec-
tion using OptiPrepTM (60% w/v  iodixanol) as a density
gradient medium following the online protocol by Axis-
Shield (www.axis-shield-density-gradient-media.com >
methodology > cells > C43). After isolation, all samples
were dissolved in RLT buffer of Qiagen (Venlo, The
Netherlands) for lysis of cells to isolate RNA, and stored at
−20 ◦C until further analysis. RNA extraction was carried
out by using Qiagen RNeasy Mini Kit (Qiagen, Venlo,
The Netherlands). The extracted amount of RNA was
quantiﬁed using a Nanodrop ND 1000 spectrophotometer
(Nanodrop Technologies) and integrity (i.e. quality) was
measured (ng/l) using an Agilent 2100 Bioanalyzer with
RNA 6000 Nanochips (Agilent Technologies, Amstelveen,
The Netherlands). Finally, samples were selected for gene
expression analysis on an AffymetrixGeneChip Rat Gene
1.1 ST plate (Affymetrix, Santa Clara, CA). One hundred
nanogram of total RNA was used for whole transcript
cDNA synthesis with the Ambion WT expression kit
[catalog number 4411974] (Applied Biosystems/Life
Technologies, Nieuwekerka/dIJssel, The Netherlands).
Hybridization, washing and scanning of the Rat Gene
1.1 ST peg arrays was  performed on a GeneTitan Instru-
ment (Affymetrix, Santa Clara, CA) according to the
manufacturer’s recommendations.
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Fig. 1. Plasma curves of isoﬂavones in F344 ovariectomized rats after a single oral gavage dose (2 and 20 mg/kg b.w.) of a commercial soy supplement. Only
daidzein and equol could be detected (the limit of detection for all SIF was  0.01 g/ml, and the limit of quantiﬁcation was 0.02 g/ml). Data are expressed
as  mean ± SD. Sample size 5 rats/group. LD () and HD () stand for low and high dose group, respectively. A signiﬁcant effect in LD and HD at speciﬁc time
rve of dapoints  is denoted by * (p < 0.01). The inserted graph shows the plasma cu
Packages from the Bioconductor project [40], integrated
in an online pipeline [41], were used to analyze the array
data. Various advanced-quality metrics, diagnostic plots,
pseudo images, and classiﬁcation methods were used as
described by Heber and Sick [42], to determine the qual-
ity of the arrays before statistical analysis. Three controls
and one HD sample did not pass the quality control criteria,
and were removed from the dataset. The ﬁnal dataset thus
obtained consisted of 11 arrays. The probes on the Rat Gene
1.1 ST array were redeﬁned using current genome infor-
mation [43]. In this study, probes were reorganized on the
basis of the gene deﬁnitions available in the National Cen-
ter for Biotechnology Information (NCBI) Rattus norvegicus
Entrez Gene database based on the rat genome build 5.1
(custom CDF v17). Normalized gene expression estimates
were calculated with the Robust Multichip Average method
[44]. Subsequently, the dataset was ﬁltered to only include
probesets (genes) that were active (i.e. expressed) in at
least 4 samples using the universal expression code (UPC)
approach (UPC score > 0.50) [45]. This resulted in the inclu-
sion of 7650 of the 19,311 (40%) probe sets present on the
array. Differentially expressed probe sets were identiﬁed
by using linear models, applying moderated t-statistics that
implemented intensity-based empirical Bayes regulariza-
tion of standard errors [46,47]. Probe sets that satisﬁed
the criterion of p < 0.05, were considered to be signiﬁ-
cantly regulated. Changes in gene expression were related
to functional changes using gene set enrichment analysis
(GSEA) performed according to Subramanian et al. [48].
GSEA focuses on groups of genes that share a common bio-
logical, biochemical or metabolic function. GSEA has the
advantage that it is unbiased, because no gene selection
step is used. Only gene sets consisting of more than 15 and
less than 500 genes were taken into account. Gene sets
were derived from the Kyoto Encyclopedia of Genes and
Genomes (KEGG) database [49]. Effects of the low and high
dose of SIF versus control were compared using ranked lists
based on signiﬁcance (t-values), using methods described
by Plaisier et al. [50].idzein during the ﬁrst 2 h.
3. Results
3.1. Kinetics
The commercial supplement used in the present
study contains predominantly daidzin (∼57%), and smaller
amounts of glycitin (∼32%) and genistin (∼11%). See also
Section 2.5. Fig. 1 shows the plasma concentrations of
daidzein and equol following a single oral administration
of a low dose of 2 mg/kg b.w. (LD) and a high dose of
20 mg/kg b.w. (HD). As is shown in Fig. 1, daidzein was
rapidly absorbed with peak plasma concentrations within
1 h after dosing. The corresponding pharmacokinetic data
are presented in Table 2. The maximum observed high-
est plasma concentration (Cmax) for daidzein was 3.2 fold
higher and the area under the curve (AUC) was 6.6 fold
larger in the HD group compared to the LD group. For equol
there was  an apparent lag time of about 1 h in both dose
groups before its appearance in plasma. Both the Cmax and
AUC for equol was  4.2 fold higher in the HD group than in
the LD group. Furthermore it can be seen from Fig. 1 that
equol is not completely cleared from the plasma within a
period of 48 h after dosing.
Fig. 2 shows the urinary and fecal excretion of SIF and
of equol, in samples collected over a 24 h period. In urine
of the LD group, the highest concentration was found for
daidzein, followed by equol and genistein, while glycitein
could not be quantiﬁed because of an interfering peak in
the chromatogram. In the HD group the highest concentra-
tion was  found for daidzein, followed by glycitein, equol
and genistein (see Fig. 2a and Table 3). The concentrations
of SIF in different dose groups were signiﬁcantly different
compared to the control group and also between the dif-
ferent dose groups. In feces highest concentrations were
found for equol, followed by daidzein and genistein (see
Fig. 2b and Table 3) and we  did not ﬁnd any conjugated SIF
(i.e. no glucosides, glucuronides or sulphates). Again due to
interference of an unidentiﬁed peak in the chromatogram
at the same retention time, it was  not possible to quantify
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Table  2
Plasma pharmacokinetic parameters of daidzein and equol in female ovariectomized F344 rats that received a single oral gavage dose (2 or 20 mg/kg b.w.)
of  SIF from a commercial SIF supplement.
Isoﬂavone dose (mg/kg b. w.)  Daidzein Equol
Cmax (ng/ml) Tmax (h) t ½ (h) AUC (g h/ml) Cmax (ng/ml) Tmax (h) AUC (g h/ml)
2 85 ± 37 0.17 2.5 0.46 20 ± 11 8 0.56
20  272 ± 36 1.0 6 3.02 83 ± 6 24 2.39
Fig. 2. Amount of isoﬂavones in urine (a) and feces (b) of F344 female ovariectomized rats over a 24 h time period after administration of a single oral dose
(2  and 20 mg/kg bw SIF) of a commercial soy supplement. Data are expressed as mean ± SD. Sample size 5 rats/group. LD and HD stand for low and high
dose, respectively. Signiﬁcant effects between LD and HD groups compared to control at speciﬁc time points are denoted * (p < 0.01) and ** (p < 0.001).
Table 3
Amount of SIF in urine and feces (g/rat) after 24 h in F344 ovariectomized rats (n = 2 for control and 5 for treatment groups). LD stands for low (i.e. 2 mg/kg
b.w.)  and HD for high (i.e. 20 mg/kg b.w.) dose. Signiﬁcant differences with the control are denoted by *p < 0.05 or **p < 0.01.
Group Daidzein Equol Glycitein Genistein
Urine Feces 1 (%) Urine Feces 2 (%) Urine Feces 1 (%) Urine Feces 1 (%)
LD 48 ± 23** 2.1 ± 1* 36 20 ± 6** 19 ± 4** 29 ND ND – 5.5 ± 3.0** 0.32 ± 0.1** 22
HD  434 ± 73** 19 ± 17 33 114 ± 38** 74 ± 30** 14 178 ± 56** ND 22 56.0 ± 12.7** 1.40 ± 0.7* 22
1 The relative amounts of the various isoﬂavones (sum in urine and feces), expressed as percentage of the administrated dose (%), was calculated based on
“aglycone equivalents” by correcting for the difference in molecular weight between the respective glucoside and its aglycon.
2 For equol, the amount was ﬁrst converted into diadzein (aglycone) equivalents and then expressed as percentage of the administrated dose of daidzin
based  on “aglycone equivalents”.
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16| P a g e
Rat Affymetrix whole genome 
array: 19311 gen es
Gene set enrichment analysis 
in high/low dose group 
compa red to co ntrol:  
639 gen e sets were regulated
80 and 59 gen e sets were 
significantly up regulated 
(FDR <0.25) in LD and HD 
groups, resp ectively.
212 and 153 gen e sets  were 
significantly down 
regulated  (FDR <0.25) in 
LD and HD groups, 
respectively
Gen e expression analysis: 
3861 and 4785 genes were significantly (p<0.05) 
regulated  in LD and HD groups, respectively compa red 
to control. The numbe r of significantl y (p<0.05) 
regulated gen es in both LD and HD groups were 3575.
1338 and 1527 gen es were 
significantly up regulated  in LD 
and HD groups, respectively.
2523 and 3258 gen es were 
significantly down  regulated  in LD 
and HD groups, respectively.
RMA normalization and filtering by only 
includ ing acti ve probe  sets (i.e . probe sets 
expressed  in at least 4 samples):
7,650 genes (40% of the total genome)
t of microarray analysis.
Fig. 4. Multidimensional scaling (MDS) plot off all arrays. The plot was
generated using the top 500 most affected genes. The distances in bothFig. 3. Flow char
glycitein in the feces of both LD- and HD-group rats. To esti-
mate the relative amount (%) recovered in urine and feces,
the administrated dose of the respective SIF as glucoside,
was converted in ‘aglycon equivalents’ using their corre-
sponding aglycone/glucoside molecular weight ratio [1].
For equol, the amount in feces and urine was ﬁrst converted
into ‘daidzein equivalent’ based on the respective molec-
ular weights and then compared with the administrated
dose of daidzin expressed as ‘daidzein equivalents’.
The relative amount of daidzein recovered in urine plus
feces collected over a 24 h period was 36% and 33% of the
administered dose of daidzin (expressed as aglycone equiv-
alents) for the LD and HD group, respectively (Table 3).
When also equol was taken into account a total of 65%
(36 + 29%) and 47% (33 + 14%) of the administrated dose
of daidzin was recovered in the LD and HD group, respec-
tively. For genistein the relative amount recovered in urine
plus feces was 22% for both the LD and the HD group. Glyc-
itin could not be detected in the urine and faces of LD rats,
and only in the feces of HD rats, at a relative amount of 22%
of the administered glycetin dose (Table 3).
3.2. Microarrays
Fig. 3 shows an overview of the microarray analysis.
Out of 7650 ﬁltered genes a total of 3861 and 4785 genes
were signiﬁcantly changed (p < 0.05) in the LD and the HD
group compared to control, respectively. Of those genes
1338 were up regulated in the LD group and 1527 in the
HD group, and 2523 genes were down regulated in the LD
group and 3258 in the HD group. Fig. 4 shows a multidi-
mensional scaling (MDS) plot that was created using the
top 500 most affected genes. Separation of the samples on
the ﬁrst dimension (i.e. X-axis), explaining most variation,dimensions are arbitrary units where LH, HD and cont. stands for low dose,
high dose and control rats, respectively.
suggests a dose response. In the 2nd dimension (i.e. Y-axis)
a smaller variation and a separation of the LD group from
the HD and control groups is observed.
In Fig. 5 the log (base 2) fold change plot of all the 7650
ﬁltered genes, without using any cut off value, in the two
different treatment groups compared to the control is pre-
sented. The upper right quadrant shows up regulation of
genes in both dose groups and the lower left quadrant






































wig. 5. Log (base 2) fold change (FC) plot of LD vs. HD groups compared to
ontrols. The log2 FC plots were prepared using data of all 7650 genes.
hows down regulation of genes in both groups. It can be
een that administration of the SIF supplement produced
 maximum 4-fold change in gene expression where more
enes were positively regulated. Moreover, there is a pos-
tive correlation (r2 = 0.96) in effects on gene expression
etween the LD and the HD group.
As the effect of SIF are expected to be induced
ia estrogen receptors (ERs), we have selected all the
strogen-responsive genes (ERGs) for the rat available in
ragon estrogen-responsive database (http://datam.i2r.a-
tar.edu.sg/ergdbV2/) which is based on the publication of
ang et al. [51]. Table 4 shows the signiﬁcantly (p < 0.05) up
nd down regulated estrogen-responsive genes (ERGs) in
he LD and HD groups. Out of 87 available rat ERGs 16 ERGs
ere found to be signiﬁcantly regulated in the LD group, of
hich 7 genes were up-regulated and 9 down-regulated.
n the HD group, 19 ERGs were signiﬁcantly regulated, of
hich 8 were up-regulated and 11 down-regulated. A num-
er of 15 ERGs were induced in the same direction in the
D and the HD group, meaning that genes that were up-
egulated in the LD group were also up-regulated in the
D group, and those that were down-regulated in the LD
roup were also down-regulated in the HD group.
As next step GSEA was performed to elucidate which
ifferentially regulated gene sets related to biological pro-
esses could be affected by treatment with SIF. Data
evealed that a total of 639 gene sets were changed in
he two treatment groups, of which 80 and 59 gene sets
ere up-regulated and 212 and 153 were down-regulated
n LD and HD group respectively, compared to the control
nd based on a false discovery rate (FDR) < 0.25 (Fig. 3).
ased on the KEGG database, Table 5 shows biological
athways (BPs) which are signiﬁcantly up (↑) or down (↓)
egulated. In total 54 KEGG based BPs were signiﬁcantly
hanged out of which 21 and 27 gene sets were up reg-
lated and 16 and 21 gene sets were down regulated in
he LD and HD group, respectively. About half of these BPs
ere affected in the same direction in the LD and the HDorts 2 (2015) 308–321 315
group (i.e. either signiﬁcantly up regulated or down reg-
ulated in both dose groups). The data show that all the
BPs related to genetic information processing such as RNA
transport and degradation and DNA replication were down
regulated. Some of the BPs related to human diseases such
as pathways related to colorectal and pancreatic cancer are
down regulated; others such as hypertrophic and dilated
cardiomyopathy were up-regulated. Also BPs related to
environmental information processing, such as extracel-
lular matrix (ECM)-receptor interactions which serves an
important role in tissue and organ morphogenesis, and
control of cellular processes such as endocytosis, phago-
cytosis, proliferation and apoptosis, were signiﬁcantly up
regulated. For a number of BPs a signiﬁcant effect was  found
in one dose group only, whereas the effect in the other
group was  non-signiﬁcant. This is for instance the case for
the citrate cycle, oxidative phosphorylation, regulation of
the actin cytoskeleton and others (see Table 5).
Fig. 6(a) presents the rank-rank scattered plot based on
the t-value of the signiﬁcantly changed and common PBMC
genes in the two dose groups of rats. Out of 7650 ﬁltered
genes (see Fig. 3) 3575 genes were signiﬁcantly changed
in both LD and HD groups, and these were used to prepare
the scatted plot. The size of quadrants in Fig. 6(a) is not
the same, because the number of signiﬁcantly down reg-
ulated genes was higher than number of signiﬁcantly up
regulated genes (see Fig. 3). A strong correlation in gene
expression proﬁle between both treatment groups (LD and
HD) relative to the controls of the rat study is observed.
4. Discussion
In this study we  evaluated the use of ovariectomized
rat model to predict (post)menopausal health risk and/or
beneﬁt of SIF supplementation by comparing transcrip-
tomics data obtained in a parallel human intervention
study in which a similar SIF supplement were given to
(post)menopausal women. The plasma concentration of
our study shows a dose dependent increase of SIF after
administration of different doses of a commercial supple-
ment. This is also reﬂected by the differences in Cmax and
AUC (Fig. 1 and Table 2). Only daidzein and its metabolite
equol could be detected in plasma, because the commer-
cial supplement contained a higher amount of daidzin than
of the other SIF. The uptake of daidzein is very fast, peak-
ing at 10 min  (see inset of Fig. 1). In the LD group, which
is the relevant dose group to be compared with the exper-
iment in human volunteers, the levels decrease, and then
rise again, with a peak at 2 h. This biphasic pattern in the
plasma concentration of daidzein, suggesting enterohep-
atic circulation, is also observed in human intervention
studies [52–54]. Franke et al. [55] mentioned that this
biphasic plasma bioavailability might occur due to the loca-
tion of uptake of SIF, where the ﬁrst early peak represent
the uptake from the small intestine and the second peak
represents the uptake from the large intestine. However,
in the HD group, with a 10 times higher dose than the LD
group, this biphasic peak did not appear. It can be suggested
that due to the higher amount of SIF in the small intestine,
compared to the LD group, a longer period is needed to
deconjugate the administered dose of SIF glucosides by the
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Table 4
List of signiﬁcantly (p < 0.05) up- and down regulated estrogen-responsive genes (ERG) in PBMC of ovariectomizedF344 rats treated with a low (LD, 2 mg/kg
b.w.)  or high (HD, 20 mg/kg b.w.) dose of SIF from a commercial supplement, compared to the control. Up and down regulation are indicated with up and
down arrows. A list of ERG in the rat can be found in the Dragon ERG database (http://datam.i2r.a-star.edu.sg/ergdbV2/).
Gene Description LD HD
ANGPT1 Angiopoietin 1 ↑ ↑
ANXA4  Annexin A4 ns ↑
BCL2  B-cell CLL/lymphoma 2 ↓ ↓
CCND2 Cyclin D2 ns ↓
CDKN1B Cyclin-dependent kinase inhibitor 1B ↓ ↓
CEACAM1 Carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) ↑ ↑
HK1  Hexokinase 1 ↑ ↑
HPCAL1 Hippocalcin-like 1 ↓ ↓
IL6R  Interleukin 6 receptor ↓ ns
ITGA6  Integrin, alpha 6 ↑ ↑
MARK2 MAP/microtubule afﬁnity-regulating kinase 2 ns ↓
NCOA1  Nuclear receptor coactivator 1 ↓ ↓
NDRG2 NDRG family member 2 ↓ ↓
PAM  Peptidylglycine alpha-amidatingmonooxygenase ↑ ↑
PHF5A  PHD ﬁnger protein 5A ↓ ↓
PSMA7  Proteasome (prosome, macropain) subunit, alpha type 7 ↓ ↓
RB1  Retinoblastoma 1 ↑ ↑
SCP2  Sterol carrier protein 2 ns ↓
 adenine
SFRP4  Secreted frizzled-related protein 4 
SLC25A4 Solute carrier family 25 (mitochondrial carrier;
ns = not signiﬁcant.
intestinal enzymes, leading to a longer absorption time in
the small intestine, thereby preventing the occurrence of a
biphasic absorption behavior. Sepehr et al. [1] also did not
observe any biphasic behavior in the plasma proﬁle of SIF in
Sprague Dawley rats receiving an oral gavage of 20 mg/kg
b.w. of a commercial soy supplement.In feces no conjugated SIFs were detected. This is in
line with other authors [38,56] reporting that SIFs are com-
pletely deconjugated by gut microbiota. In both the LD and
HD group the equol concentration was signiﬁcantly higher
Fig. 6. Rank–rank scattered plot for signiﬁcantly changes in gene expression am
group  compared to (post)menopause women (b). A similar picture was  found f
ﬁltered genes (see Fig. 3) 3575 genes were signiﬁcantly changed (p < 0.05) in b
were  signiﬁcantly changed (p < 0.05) in both rat and homologous human PBMC. 
represents the t-value of a single gene. Corresponding human homologous genes 
same supplement, in a similar dose as the LD rats [23]. Genes signiﬁcantly chan
I  and III, while genes signiﬁcantly changed in opposite directions are in quadran
among  the two  different groups.↑ ↑
 nucleotide translocator), member 4 ↓ ↓
compared to daidzein, indicating an efﬁcient conversion of
daidzein into equol by rat colonic microbiota [57,58]. The
later appearance of equol in plasma compared to daidzein
is also consistent with its production in the large intes-
tine [1,59]. All rats are equol producers and several colonic
bacteria are involved in the production of equol in rats
[59]. However, only 25–30% of the adult Western popu-
lation is able to produce equol due to lack of the speciﬁc
colonic microbiota. This percentage is signiﬁcantly lower
than in Eastern Asian populations where more than 50%
ong the LD and the HD group relative to the controls (a), and for the LD
or HD rats vs. (post)menopause women (data not shown). Out of 7650
oth LD and HD groups; while out of 7650 ﬁltered genes, only 69 genes
These 3575 and 69 genes were used to build the scattered plot. Each dot
were retrieved from the study with (post)menopausal women  taking the
ged in the same direction in both treatments are in Cartesian quadrants
ts II and IV. The density of the dots visualize similar trends in regulation
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Table  5
Gene set enrichment analysis (GSEA) of KEGG based signiﬁcantly regulated (FDR < 0.25) biological pathways (BPs) in the PBMC of ovariectomized F344 rats
treated  with a commercial supplement compared with control. LD and HD stands for low and high dose groups, while up and down regulated enrichments
are  indicated by up and down arrows. The names of the different pathways are literally quoted from KEGG together with the number of genes involved in
the  speciﬁc pathways.
BPs related to BP No. of Genes cLD c cHD c
Mebabolism
Citrate cycle (TCA cycle) 24 ↓ ns
Oxidative phosphorylation 82 ↓ ns
Glutathione metabolism 30 ↑ ↑
N-glycan biosynthesis 36 ↓ ↓
Porphyrin and chlorophyll metabolism 17 ↑ ↑
Genetic  information processing
Basal transcription factors 22 ↓ ns
Spliceosome 94 ↓ ↓
Aminoacyl-tRNA biosynthesis 25 ↓ ns
Ribosome biogenesis in eukaryotes 56 ↓ ↓
Ribosome 35 ↓ ↓
RNA  transport 105 ↓ ↓
mRNA surveillance pathway 52 ↓ ↓
RNA  degradation 49 ↓ ↓
Proteasome 40 ↓ ns
Protein export 18 ↓ ↓
Protein processing in endoplasmic reticulum 129 ↓ ns
DNA  replication 28 ↓ ↓
Base  excision repair 18 ↓ ↓
Mismatch repair 19 ns ↓
Environmental information
processing
ABC transporters 15 ↑ ns
Neuroactive ligand-receptor interaction 33 ↑ ns
ECM-receptor interaction 19 ↑ ↑
Cellular processes
Lysosome 92 ns ↑
Endocytosis 126 ↑ ↑
Phagosome 90 ↑ ↑
Regulation of actin cytoskeleton 104 ↑ ns
Focal  adhesion 81 ↑ ↑
Gap  junction 37 ↑ ↑
Organismal System
Complement and coagulation cascades 16 ↑ ↑
Toll-like receptor signaling pathway 54 ↓ ns
Hematopoietic cell lineage 45 ↑ ↑
Natural killer cell mediated cytotoxicity 63 ns ↓
T  cell receptor signaling pathway 77 ↓ ↓
Intestinal immune network for IGA production 20 ns ↓
PPAR  signaling pathway 26 ↑ ↑
Cardiac muscle contraction 29 ns ↑
Vascular smooth muscle contraction 50 ↑ ns
Pancreatic secretion 37 ↑ ns
Aldosterone-regulated sodium reabsorption 18 ↓ ns
Long-term depression 31 ↑ ns
Circadian rhythm – mammal 15 ↓ ↓
Human  disease
Pathways in cancer 142 ↓ ↓
Chagas disease (americantrypanosomiasis) 59 ↓ ↓
Malaria 23 ↑ ↑
Colorectal cancer 46 ↓ ↓
Pancreatic cancer 41 ns ↓
Primary immunodeﬁciency 26 ns ↓
Parkinson’s disease 81 ↓ ns
Huntington’s disease 109 ↓ ns
Prion  diseases 18 ↓ ns














f all adults can produce equol [25,48,59]. Sepehr et al. [1]
eported that dosing Sprague-Dawley rats (both male and
emale) with a mixture of all three SIF glucosides or a com-
ercial SIF supplement increases the production of equol
ompared to dosing with aglycone alone. In vitro studies
ith human colonic bacteria suggested that a high carbo-
ydrate environment stimulates the colonic fermentation
nd increases the rate of conversion of daidzein into equol
16,17].ardiomyopathy (arvc) 20 ↑ ns
25 ↑ ↑
18 ↑ ↑
From the transcriptomic analysis it appears that out of
the 19,311 gene probes on the array chip about 20–25%
genes were signiﬁcantly changed in the different dose
groups compared to the control (Fig. 3). To the best of our
knowledge there is no literature available on the effect
of soy supplementation on gene expression in rat PBMC,
therefore, it was  not possible to directly compare our
PBMC data with published data. However in the parallel
study of van der Velpen [23] PBMC of (post)menopausal
logy Rep318 M.A. Islam et al. / Toxico
equol-producing human volunteers, exposed to the same
SIF supplement, only 2% of the total number of genes was
signiﬁcantly changed. This suggests that rats might be more
susceptible to effects of SIF than humans. It is unclear, how-
ever, to what extent the inbred nature of the rats could have
contributed to this difference. In both studies the transcrip-
tomic data were produced and analyzed in the same labo-
ratory, thus preventing intra laboratory variation between
the two studies. It is generally known that rats have a higher
metabolic potency compared to humans which is also true
for SIF [17]. Therefore a higher enzymatic activity in rats
might probably results in a higher number of affected genes
[60]. In the rat study also a strong dose dependent correla-
tion was shown by the rank-rank scattered plot (Fig. 6a) and
the log (base 2) analysis (Fig. 5). We  also found that about
20% of the total rat ERGs was signiﬁcantly changed: 16 and
19 ERGs were signiﬁcantly regulated in LD and HD group,
respectively out of 87 ERGs. Some of the affected ERGs are
involved in important biological endpoints that might be
related to beneﬁcial health effects like lower risks for breast
cancer as observed in epidemiological studies [13,61]. For
example, the RB1 (retinoblastoma1) gene, which is up reg-
ulated in the present study after SIF treatment, is a tumor
suppressor gene, and a negative regulator of the cell cycle
[62]. Hanahan and Weinberg [64] stated that down regula-
tion of the retinoblastoma protein pathway by the RB1 gene
is a “hallmark of cancer”. Down regulation of RB1 is posi-
tively correlated with tumor formation and in our present
experiment this RB1 gene was up regulated, indicating a
possible beneﬁcial effect of SIF supplementation on tumor
formation.To investigate whether the observed effects in rats are
predictive for effects in humans, the gene expression data
from the present rat study were compared with the data of
van der Velpen et al. [23] who performed a parallel human
Table 6
List of the signiﬁcantly expressed human estrogen responsive genes (ERGs) in PB
expression in PBMC genes in the present rat study. LD and HD stands for low an
indicated by up and down arrow marks.
Genes Description 
BCL2L1 BCL2-like 1 
CACYBP Calcyclin binding protein Y 
EDEM1  Endoplasmatic reticulum degradation enhancer, mannosida
ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2
derived oncogene homolog (avian)
FKBP5  FK506 binding protein 5 
FOXP1  Forkhead box P1 
HSPA1A Heat shock 70 kDa protein 1A Y 
MYB  v-mybmyeloblastosis viral oncogene homolog (avian) 
NME2  NME/NM23 nucleoside diphosphate kinase 2 Y 
NRP1  Neuropilin 1 Y 
PSMD8 Proteasome (prosome, macropain) 26S subunit, non-ATPase
PTPRO  Protein tyrosine phosphatase, receptor type, O Y 
SLC25A5 Solute carrier family 25 (mitochondrial carrier; adenine nuc
member 5
SPRED1 Sprouty-related, EVH1 domain containing 1 Y 
STAB1  Stabilin 1 Y 
STXBP1 Syntaxin binding protein 1 
TIMELESS Timeless homolog (Drosophila) 
a – absent; ns – not signiﬁcant.orts 2 (2015) 308–321
intervention study. They found that of the 1069 human
ERGs mentioned in the Estrogen Responsive Gene Database
[51] only 17 human ERGs were signiﬁcantly changed, of
which 7 were up regulated and 10 were down regulated.
We have investigated whether these 17 human ERGs are
also signiﬁcantly regulated in the present rat study. Table 6
shows the signiﬁcantly expressed ERGs in PBMC of human
volunteers reported by van der Velpen et al. [23] and their
expression in PBMC of rats of the current study. It is shown
that 10 out of these 17 genes were common in both rat
and human PBMC. Seven of these 10 genes were signif-
icantly changed, but only 3 were changed in the same
direction in rats and humans: CACYBP and NME2 were up-
regulated and STXBP1 was down-regulated. It is interesting
to note that more than half of the number of human ERGs
is also found in rat PBMC and that most of them are sig-
niﬁcantly affected by SIF treatment. However, most of the
common genes are regulated in opposite directions in rats
and humans. This means that if they are up regulated in
human PBMC they are down regulated in rat PBMC or if
they are down regulated in human PBMC they are up regu-
lated in rat PBMC. Therefore rat PBMC do not seem to be a
suitable model to predict effects of SIF treatment on ERGs
in human PBMC. It should, however, be noted that these
human genes identiﬁed as ERGs by the Estrogen Respon-
sive Gene Database [51], and also found in rat PBMC, are
not identiﬁed as rat ERGs by the Dragon Database. Further
information is needed to conclude whether these genes are
also estrogen responsive in rats.
When the signiﬁcantly changed and common PBMC
genes in the LD group of the rat study and the human inter-
vention study by van der Velpen et al. [23] were compared,
it was found that only 69 common genes were signiﬁcantly
changed in both rat and human PBMC. However, in the
rank-rank scattered plot (Fig. 6b) no overall correlation for
MC of human volunteers reported by van der Velpen et al. [23] and their
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he changes in PBMC of rats and humans was observed.
lso for the HD group of the rat study no correlation with
he results and the human intervention study was found
data not shown). This lack of correlation is in line with the
bservation that of the common affected ERGs in rat and
uman PBMC. Only three were changed in the same direc-
ion. Another important example of a gene that is affected
n a different direction in rat and human is BCL2 which is up
egulated in human indicating induction of apoptosis [33]
ut down regulated in rat.
In the present study we have observed beneﬁcial effect
f SIF on ovariectomized rat but also signiﬁcant species
ifferences in the changes in gene expression in PBMC
f rats and humans following comparable exposure to a
ommercial SIF supplement. Setchell et al. [63] also found
igniﬁcant species differences of the circulating concen-
rations of aglycones among rodent and human. Based on
ifferences in the proportion of unconjugated SIF in plasma
f humans in rodents, in particularly for certain strains
f mice, they also questioned the value of these rodent
odels for the assessment of effects of SIF in humans. How-
ver, in the article of Setchell et al. [63] different isoﬂavone
ources and administration protocols were used to treat
nimals and human volunteers. Animals were treated with
uch higher dose levels compared to humans. In addition
he adult human data span wide range of ages (i.e. from
1 to 65 years). Therefore, the higher aglycone concen-
rations of IF in the plasma of rats compared to that of
umans may  also be due to the higher dose levels used
n the rat studies and enzymatic variation among differ-
nt age group of human individuals. In our present study
e have overcome these difﬁculties by using the same
ource and dose level to compare plasma bioavailabil-
ty and PBMC gene expression of ovariectomized rat with
quol producing menopause women. To further increase
he comparability of rat data with human data, only equol
roducing menopausal women were included in the par-
llel human study because all rats are equol producers,
hile only 25–30% of the Western populations are equol
roducers [59].
However, the comparison of the results of the current
at study with those of the parallel study with human vol-
nteers [23] indicates that the rat might not be a suitable
odel to predict effects of SIF in humans. It should, how-
ver, be recognized that, although the relative exposure
eriod in rats and the human volunteers (i.e. 0.27% for
at and 0.22% for humans, see Section 2.4) in relation to
heir respective life span is comparable, longer term repet-
tive administration of rats to SIF may  be needed to draw a
nal conclusion on the suitability of the rat model, because
onger exposure might lead to a difference in gene expres-
ion [62].
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